Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 1269-1270, 2004; 10.1373/clinchem.2004.031609
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costa, C.
Right arrow Articles by Goossens, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costa, C.
Right arrow Articles by Goossens, M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2004;50:1269-1270.)
© 2004 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Quantitative Real-Time PCR Assay for Rapid Identification of Deletion Carriers in Hemophilia

Catherine Costa1,2,a, Jean-Marie Jouannic3, Nathalie Stieltjes4, Jean-Marc Costa5, Emmanuelle Girodon1,2 and Michel Goossens1,2

1 Laboratoire de, Génétique Moléculaire, Centre Hospitalier Universitaire, Henri Mondor AP-HP, Créteil, France, 2 INSERM U468, Créteil, France, 3 Service de Médecine Foetale, Institut de Puériculture de Paris, Paris, France, 4 Centre de Traitement des Hémophiles, Groupe Hospitalier Cochin, Saint Vincent de Paul, Paris, France, and 5 Centre de Diagnostic Prénatal, Hôpital Américain de Paris, Neuilly/Seine, France

aAddress correspondence to this author at: Service de Biochimie-Génétique, Laboratoire de Génétique Moléculaire, Centre Hospitalier Universitaire Henri Mondor, 51, av. du Mal-de-Lattre-de-Tassigny, 94010 CRETEIL Cedex, France. Fax 33-1-49-812-842; e-mail costa@im3.inserm.fr.

The first 20% of the full text of this article appears below.


To the Editor:

Gene deletions are common events in various hereditary diseases, but conventional PCR often fails to detect such defects in heterozygous patients (1). This highlights the need for a suitable method, easily applicable in a diagnostic laboratory (2). Large deletions account for ~5% of cases of hemophilia, inherited as a recessive X-linked disease, making determination of carrier status difficult. It is of particular importance when a pregnant woman is carrying a male fetus. Prenatal testing that uses invasive methods of sample collection carries a risk of miscarriage or fetal injury, and is unnecessary if the woman is not a carrier. We designed a real-time quantitative PCR assay to establish heterozygous status for deletion carriers and to avoid such risky situations in a family in which a large deletion of the F9 gene was . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 haematolHome page
A. Vencesla, M. J. Barcelo, M. Baena, M. Quintana, M. Baiget, and E. F. Tizzano
Marker and real-time quantitative analyses to confirm hemophilia B carrier diagnosis of a complete deletion of the F9 gene
Haematologica, November 1, 2007; 92(11): 1583 - 1584.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.